olipudase alfa Special Drug Use Investigation for the patients with acid sphingomyelinase deficiency

olipudase alfa Special Drug Use Investigation for the patients with acid sphingomyelinase deficiency - olipudase alfa Special Drug Use Investigation for the patients with acid sphingomyelinase deficiency

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048091

Enrollment

2147483647

Registered

2022-06-17

Start date

2022-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acid sphingomyelinase deficiency

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: all subjects treated with XENPOZYME

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Incidence during the observation period of adverse drug reaction, mainly safety specification events	—

Countries

Japan

Contacts

Public ContactMasahiro Tamura

Medical Affairs Post-authorization regulatory studies

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results